Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients.
Renal cancer cells from 43 patients and normal renal cells from 10 of them were studied for the expression of highly stress-inducible heat shock protein 72 (HSP72) by means of immunoperoxidase analysis. It was found that HSP72 was expressed in a significantly higher percentage of renal cancer cells than normal renal cells (P = 0.0001), the mean percentage of positive cells being 33.1 +/- 18% and 8 +/- 5%, respectively. Moreover, a percentage of HSP72-positive cells that was less than the cut-off point (18%, mean value of normal cells +2 S.D.) significantly correlated with shorter disease-free survival (P = 0.002). The renal cancer cell populations taken from the 21 patients who relapsed after a median time of 13 months (range 3-73 months) had a significantly lower percentage of HSP72-positive cells (mean value 25.1 +/- 17%) than the cells taken from the patients who remained tumour-free (mean value 40.8 +/- 15%) after a median period of 72 months (range 19-96 months, P = 0.003). It was also demonstrated that HSP72 expression can be significantly increased by 48-h in vitro incubation with rIFN-gamma (P = 0.007). These data suggest that HSP72 may represent a favourable prognostic factor regardless of stage and histological grade and its expression may be increased by treatment with rIFN-gamma. Further studies are needed in order to investigate the relationship between HSP72 and the immunoeffector cells.
Santarosa
M
M
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Favaro
D
D
Quaia
M
M
Galligioni
E
E
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism*; D005260:Female; D050884:HSP72 Heat-Shock Proteins; D006360:Heat-Shock Proteins / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D007371:Interferon-gamma / Q000494:pharmacology; D007668:Kidney / Q000737:chemistry; D007680:Kidney Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D050884:HSP72 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D011994:Recombinant Proteins; D007371:Interferon-gamma